Familial Lipoprotein Lipase Deficiency Pipeline Report Highlights
The companies and academics are working to assess challengesand seek opportunities that could influence Familial Lipoprotein LipaseDeficiency R&D. The therapies under development are focused on novel approaches to treat/improve Familial Lipoprotein Lipase Deficiency.
Familial Lipoprotein Lipase Deficiency Pipeline: Emerging Drugs Chapters
This segment of the Familial Lipoprotein Lipase Deficiencyreport encloses its detailed analysis of various drugs in different stages ofclinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Familial Lipoprotein Lipase Deficiency Emerging Drugs
IONIS-APOCIII-LRx: Ionis Pharmaceuticals
IONIS-APOCIII-LRx, formerly known as AKCEA-APOCIII-LRx, is aligand-conjugated (LICA) investigational antisense medicine designed to inhibitthe production of apoC-III, for patients who are at risk of disease due to elevated triglyceride levels. The drug is in Phase III clinical evaluation for the treatment of familial lipoprotein lipase deficiency.
ARO-APOC3: Arrowhead Pharmaceuticals
ARO-APOC3 is a subcutaneously administered RNAi therapeuticthat targets apolipoprotein C-III (apoC-III), and reduces VLDL synthesis andassembly, enhances the breakdown of triglyceride rich lipoproteins, and improve clearance of VLDL and chylomicron remnants. The drug is in Phase II clinical studies for the treatment of familial lipoprotein lipase deficiency.
Learn for more information about Familial Lipoprotein Lipase Deficiency Pipeline Insights
Recommended Reports
